The company and all members of the board guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or significant omissions. Recently, Lizhu Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") announced that its subsidiary, Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd. (hereinafter referred to as "Lizhu Monoclonal Antibody"), has received the Drug Registration Certificate (Certificate No.: 2026S01827) issued by the National Medical Products Administration. The details are as follows:
000513SZSE
🚨 Material Event
Announcement on Obtaining the Drug Registration Certificate
✨ AI Summary
The company announces that its subsidiary, Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd., has received a Drug Registration Certificate for Recombinant Human Follitropin Alfa Solution for Injection. The product is approved for use in treating anovulation and assisting reproductive technologies. The total R&D investment for this drug has reached approximately RMB 121.69 million. Investors are advised to be cautious due to market uncertainties.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.